Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CABOTEGRAVIR Cause Virologic failure? 275 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 275 reports of Virologic failure have been filed in association with CABOTEGRAVIR (Apretude). This represents 3.3% of all adverse event reports for CABOTEGRAVIR.

275
Reports of Virologic failure with CABOTEGRAVIR
3.3%
of all CABOTEGRAVIR reports
5
Deaths
15
Hospitalizations

How Dangerous Is Virologic failure From CABOTEGRAVIR?

Of the 275 reports, 5 (1.8%) resulted in death, 15 (5.5%) required hospitalization, and 1 (0.4%) were considered life-threatening.

Is Virologic failure Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CABOTEGRAVIR. However, 275 reports have been filed with the FAERS database.

What Other Side Effects Does CABOTEGRAVIR Cause?

Product dose omission issue (1,121) Off label use (1,049) Injection site pain (924) Viral load increased (452) Pain (399) Pathogen resistance (270) Pyrexia (255) Product use in unapproved therapeutic environment (234) Inappropriate schedule of product administration (228) Product complaint (213)

What Other Drugs Cause Virologic failure?

LAMIVUDINE (1,894) EFAVIRENZ (916) TENOFOVIR DISOPROXIL (896) NEVIRAPINE (813) DOLUTEGRAVIR (770) ZIDOVUDINE (741) RITONAVIR (594) RALTEGRAVIR (517) ABACAVIR (490) LOPINAVIR\RITONAVIR (428)

Which CABOTEGRAVIR Alternatives Have Lower Virologic failure Risk?

CABOTEGRAVIR vs CABOTEGRAVIR\RILPIVIRINE CABOTEGRAVIR vs CABOZANTINIB CABOTEGRAVIR vs CABOZANTINIB S-MALATE CABOTEGRAVIR vs CAFFEINE CABOTEGRAVIR vs CALASPARGASE PEGOL

Related Pages

CABOTEGRAVIR Full Profile All Virologic failure Reports All Drugs Causing Virologic failure CABOTEGRAVIR Demographics